Hello, thank you for attending the Butterfly Network Q3 2023 earnings call. My name is Victoria, and I'll be your moderator today. All lines will be muted during the presentation portion of the call, with an opportunity for questions and answers at the end. In the upcoming remarks, there will be references to video clips that will not be animated on the live slides. We anticipate the animated video version of the slides will become available online at ir.butterflynetwork.com within 24 hours of today's call. I would now like to pass the conference over to your host, Heather Getz. Thank you. You may proceed, Heather. Good morning, and thank you for joining us today. Earlier today, Butterfly released financial results for the third quarter ended September 30, 2023, and provided a business update. The release and earnings presentation, which include a reconciliation of management's use of non-GAAP financial measures compared to the most applicable GAAP measures, are currently available on the investor section of the company's website at ir.butterflynetwork.com. I, Heather Getz, Chief Financial and Operations Officer of Butterfly, alongside Joseph DeVivo, Butterfly's Chairman and Chief Executive Officer, will host today's call. During today's call, we will be making certain forward-looking statements. These statements may include, among other things, expectations with respect to financial results, future performance, development and commercialization of products and services, potential regulatory approvals, and the size and potential growth of current or future markets for both our products and services. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our filings made with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligation to update such statements. As a reminder, this call is being webcast live and recorded, and we will be referencing a slide presentation in conjunction with our remarks. There may be a short delay between the live telephone audio and the presentation being shown. To access the webcast, please visit the Events section of the Investor Relations section of our website, and a replay of the event will be available following the call. I would now like to turn the call over to Joe. Joe? Thank you, Heather. So it's a pleasure to speak with you all today. I'm excited to share our results and the progress we've made in our business transformation since I joined just about six months ago. As I noted on our last earnings call, Butterfly Network is a great technology platform with leading products and services. We're now focused on not only providing the best point-of-care ultrasound solutions, but also expanding our addressable market through adjacencies to return the company to organic growth. We've made some great progress in the third quarter, including a number of exciting announcements, while continuing to execute against our operational plan, and as a result, we remain on track to meet our fiscal 2023 guidance of at least $64 million in revenue and provide improved EBITDA guidance. Butterfly's go-to-market strategy is centered on our proprietary semiconductor technology and accompanying software. We continue to successfully execute against it, positioning us on a path to growth. First, we sought to identify and disrupt a market that our product and technology could displace, and we did: point-of-care ultrasound. Here, we have the most versatile handheld device at the most competitive price point, and we already have a large and growing share in terms of units sold globally. With new entrants and established players following the path to investment in ultrasound AI, even introducing new devices that are also chip-based, albeit still relying on piezo crystals, we've successfully proven this to be a viable and growing market that we will continue to win in. The next part of our roadmap, which we are currently executing on, is to continue to grow and develop the POCUS market while identifying new use cases for our proprietary semiconductor chip and software to address. The upcoming launch of Butterfly iQ3 and our recent co-development partnership announcement, which I'll discuss in a few minutes, are but two examples of Butterfly successfully executing this strategy as we move through the second half of 2023 and into 2024. Further out, as our core technology and software evolve, we'll move into wearable form factors to build markets that no one else can. On the last call, I shared with you a number of near-term strategic initiatives our team is taking to accelerate our growth. Namely, these are, one, introducing new products like iQ3 to strengthen and solidify our position as the leading POCUS handheld. Two, introducing new education offerings to enhance POCUS competency and drive awareness and adoption. Three, accelerating ease of use and access to AI tools through Butterfly Garden, our partner ecosystem. Four, identifying growth areas outside of POCUS application through our Powered by Butterfly chip development partnerships. I'm happy to report that our team is delivering on all of these efforts, with significant progress made in this past quarter. We're confident that these will be meaningful contributors to our 2024 numbers. Operationally, as we mentioned last quarter, from August of 2022 to July of 2023, management took steps to eliminate $170 million of operating costs from our expense structure. In this transition year, we're making the business more efficient while we continue to invest in long-term growth and innovation. Importantly, our focus on expense reduction and cash preservation does not end here as we continue to identify ways to increase productivity and efficiency. Simultaneously, we've been investing in new product development to support Butterfly's growth. In the U.S., we hired several new salespeople and managers to increase the footprint of our U.S. organization, focus on enterprise deals. For international, under new sales leadership, we're working on opening several new markets while partnering with distributors to move current inventory. And in vet, we're testing our current AI tools on other more lucrative animal groups, including cattle. We're confident that these investments in our team and capabilities will reap benefits going forward. Now I'll move to our strategic initiatives. As mentioned, education is a top priority and one of the ways we're expanding our addressable market. The Butterfly paradox is that we continue to make ultrasound accessible through cost and product quality, yet ultrasound remains the most difficult to master imaging modality. This quarter, we're attacking this challenge head-on by introducing two new additions to our suite of educational offerings. In September, we launched the Butterfly Certified Program, which is actively being quoted by our sales force. Butterfly Certified is a series of live training opportunities with virtual and in-person options that target improving user proficiency for one or multiple exams. The customer can purchase a range of services, from a virtual scan review to a full year course to be a certified trainer. By providing these solutions, we can accelerate focus adoption and give a clear roadmap of success to our customers. So continuing education, recently at the American College of Emergency Physicians annual meeting, known as ACEP, Butterfly previewed our new Scan Lab app. The app uses AI and anatomical labeling tools to demystify ultrasound to a new user, and teaches learners how to place a probe on the body to get the desired image. As you can see on this slide, the user has selected an Apical four-chamber view. On the left, there's a walkthrough with a reference imaging and specific instructions. Before the user scans, they see an example of what the video should look like on the right, and when they plug their Butterfly probe and start scanning, live ultrasound image comes up, and the anatomic labels tag each part of the anatomy. This helps to make ultrasound imaging more approachable, building users' confidence as they begin their ultrasound imaging journey. The app will also support existing users in extending their skills and drive success in medical education by helping schools further engage and empower students to embrace ultrasound learning and development. Early reception at ACEP for Scan Lab was very encouraging, and we look forward to launching the app to all existing Butterfly subscribers for free. We expect Scan Lab access to continue to drive adoption and software sales to existing and new users once launched in early 2024. With our Butterfly Academy online modules, Scan Lab app, Butterfly Certified services, today we have the most powerful and complete pathway to success for new ultrasound users. I'm proud of the team for making both of these initiatives happen so quickly and executing effectively this quarter. Last quarter, we introduced Butterfly Garden, and our plans to build a partnership ecosystem for accelerating access to new ultrasound AI. As you know, Butterfly has the largest handheld install base in the world, with over 100,000 units placed and growing. AI developers want access to our customers, who want access to their solutions on their Butterfly. We launched Butterfly Garden at the beginning of the quarter. Since then, we've received inquiries from over 100 prospective partners. We've already signed three universities, including Caltech, University of Maryland, and UNC. Dr. Stringer's team at UNC recently published impressive findings about the auto gestational age AI tool they built on Butterfly for maternal health, which you can see on the slide. Under Butterfly Garden, they're expanding that into a tool to auto-detect multiple fetal conditions. We've also signed leading AI companies like ThinkSono and others not yet announced publicly. Our business model is to charge partners an annual fee to maintain the software development kit or SDK, as well as a revenue share on their future apps sold to Butterfly customers. So relatedly, we also announced our first Powered by Butterfly deal with Forest Neurotech. Powered by Butterfly represents the next level of Butterfly-enabled development, where partners not only have access to our SDK, but also to our novel Ultrasound-on-Chip. This allows them to develop around the core technology and bring it to non-competitive markets to Butterfly. This way, Butterfly investors can capitalize on those new markets and gain significant leverage as each of these companies reach their goals through commercial success. Forest Neurotech is founded by a group of brilliant engineers and entrepreneurs with track records of bringing disruptive healthcare technology to market. It is backed by Eric Schmidt, a founder of Google, and Citadel's Ken Griffin. They intend to use our chip to create a brain-computer interface, which will be a minimally invasive implant able to scan and process the brain to understand where therapies are needed. The jointly developed technology will also treat those areas. Remember, our chip is uniquely capable of moving the ultrasound beam through the body without having to move the device. We look forward to announcing another Powered by Butterfly deal in the fourth quarter. Again, I'm proud of our team for executing on these growth initiatives. Both Powered by Butterfly and Butterfly Garden offer meaningful new sources of revenue for the company. We anticipate them becoming positive contributors to our numbers in 2024 and beyond, while also enriching our platform for our users. So moving on. Many of you know Moore's Law, as seen on this slide, states that the number of transistors on a chip will double every two years, meaning the computer processing power doubles every two years. We all know how many industries were transformed using digital technology. So what I'd like to highlight is photography, which is similar to ultrasound imaging. After the digital camera was launched in 1993, most users saw it as an interesting and novel tool, but didn't really take it seriously because image quality did not rival film. In 1997, 2001, and 2003, digital camera manufacturers continued to benefit from Moore's Law and delivered 2, 5, and 7 MB images. In 1995, for the first time in history, digital cameras outsold film cameras when the image quality was perceived to be equal. Once digital equals analog, analog loses, because all the digital benefits, such as no cost to develop film, better storage, become the tiebreaker and buyer behavior shifts to those benefits. I believe it's inevitable that analog piezoelectric crystals ultrasound will be a thing of the past, like film camera is today. Piezo crystals make good images, but provide fixed lenses, are limited in their frequencies, and are heat inefficient. They also require multiple probes to achieve Butterfly's whole body scanning range. That will never change. It's just physics. That goes for piezoelectric-based chips or PMUTs as well. Crystal-based carts require sophisticated arrays and wiring. These mechanisms are fragile and expensive to fix. With digital scanning instead, I believe piezo-based carts will be obsolete by the end of the decade. With that said, on my first call, I told you I felt like I was a kid in a candy store when I reviewed all that is in Butterfly's R&D pipeline. I also told you that I'd show you one of our new hardware devices before the end of the year, and now I'm gonna do just that. This is iQ3, our third generation platform and fifth iteration of our processor. In addition to a marked improvement in image clarity and better ergonomic design, there will be many new one-of-a-kind capabilities that will change the way we can capture and review images. I'm not going to unveil them today. We need to keep a couple competitors who like to copy Butterfly guessing, but what I'll show you is iQ3's improved processing power and image quality. This next generation device has double the data rate transfer for better and faster ultrasound beam control and improved image quality, and will fully charge in less than half the time. The improved processor is so powerful, its image quality is now equal to, and arguably exceeds, analog devices like GE's Vscan, a benchmark competitor for cardiac imaging. We believe iQ3 even rivals some cart-based systems. In our opinion, we've met that turning point where image quality associated with more expensive handhelds will no longer be a barrier, and our digital capabilities will compel users to move completely to Butterfly, all while being at a more competitive price point. So let's look at a couple images. We'll start with lung. Our lung scanning is already best-in-class. As you can see, iQ+ here in the middle delivers excellent images, and for most ER and primary care use cases, it's an excellent option. You can see the middle image, iQ+, shows a distinct set of A-lines visible as bright horizontal lines throughout the image, with minimal drop-off in the far field or the bottom of the image. iQ+ A-lines are arguably even more distinct than Vscan's on the left. But when you look at the right in iQ3, the bar is clearly raised. It has sharp, defined A-lines all the way into the far field. Now, here's a four-chamber view or kind of a cardiac money shot. You can see Vscan here on the left, and iQ+ is right next to it. Quite close in quality, though the slower frame rate of Vscan gives the perception of the heart beating slower. And iQ+ already has a wider field of view that's able to include the ventricular walls. Now, take a look at iQ3. Just incredible what it looks like, with even better frame rate and fewer ventricular artifacts. It's amazing how this much clarity can be delivered in a compact, all-in-one probe that is still less expensive than analog counterparts. You can see here clearly that iQ3 can be used for the most challenging images. As a single probe, allowing the user to effortlessly choose a different preset and scan anywhere in the body. The benefits of digital come shining through when all becomes equal. Did I mention that our next generation chip is well underway? So those carts, beware. So we've heard about the new PMUT chip being previewed by a competitor. We haven't gotten a device to test with it like we have with the others, but we have taken all the images they've put online and compared them to our images, assuming that they've put their best foot forward. Here is a PMUT, then iQ+, and then iQ3. Butterfly iQ+ maintains the B-mode image quality simultaneously with Color Doppler enabled, and the hemodynamic color fill is good. Then with iQ3, we have even better color sensitivity and true real-time hemodynamic flow. In our opinion, the PMUT chip image doesn't present even as well as our second-generation iQ+, nevertheless, iQ3. But see for yourself. So we're hopeful the iQ3 is approved for sale by the end of the first quarter of 2024, and we'll be off to the races then. We're preparing every phase of our business for this launch and are gearing for the demand. At the recent ACEP meeting, we previewed iQ3 for thought leaders around the country. I personally saw their excitement when they viewed the image that they didn't think would be possible this soon on a Butterfly. They also loved the new advanced digital capabilities, which I'll show you next quarter. So thank you for indulging me in this demonstration. I look forward to unpacking more about iQ3 for you soon. We believe 2024 will be the year where digital ultrasound imaging becomes equivalent to higher-end handheld probes. All this to say, why should hospitals own multiple probes with poor battery life and runtimes that are too hot to the touch? Very soon, they can just put them in the drawer next to their Kodak cameras. With that, I'll turn it over to Heather. Heather? Thank you, Joe. Revenue for the third quarter of 2023 was $15.4 million, down compared to the prior year revenue of $19.6 million, driven by lower volume, partially offset by higher price. The lower volume was driven by two large deals last year, Gates and Rochester, that did not repeat in the current year. In the U.S., we realized $10.4 million in total sales, lower than prior year. This was driven by lower probe sales, largely from Rochester, which was partially offset by higher subscription revenue and higher ASPs. Total international declined to $3.8 million. This is due to the second deployment of the probes for the Gates grant in Africa in the prior year quarter. Excluding Rochester and Gates, the U.S. and international were essentially flat. Breaking our revenue down between product and software. Product revenue was $8.8 million, a decrease of 34% versus Q3 2022. This decrease was driven by lower volume spread largely across U.S. and international due to the large deals in 2022 that I mentioned. Software and services revenue was $6.7 million in the third quarter, growing by 3% over the prior year period. Software and services mix was 43% of revenue and increased approximately 10 percentage points versus Q3 2022. This increase was due to a higher installed base of subscription software as compared to in-period probe sales, renewals on the existing base of software users, and software implementations completed during the quarter. Our total annual recurring revenue, which is reported as part of software and other services, grew by 19%. This was led by a strong increase of 51% in our enterprise software, which increased from 31% to 40% of our total ARR. Turning now to gross profit. Gross profit was $9.4 million in Q3 2023, compared to $11 million in the prior year period. Gross profit margin was 61% for the third quarter, which compares to 56% in the third quarter of 2022. This increase was primarily due to a higher average selling price, in addition to the shift in product mix, reflecting a higher proportion of higher-margin software and other services revenue. Also contributing to the increased margin was higher manufacturing productivity and other efficiencies. Offsetting these benefits was higher amortization. For the third quarter of 2023, adjusted EBITDA loss was $12.5 million, compared with a loss of $31.8 million for the same period in 2022. The improvement in adjusted EBITDA loss was driven by the implemented cost reductions, which led to lower payroll, consulting, and other outside services. Moving to our capital resources, as of September 30, 2023, cash and cash equivalents, including restricted cash, were $154 million. Our total use of cash in the third quarter was $17 million. If I exclude $3 million of non-recurring expenses, our monthly use of cash was down to under $5 million in the third quarter. Moving on to guidance. As Joe discussed, we have been executing against the roadmap we laid out in August. We launched Butterfly Garden, filed iQ3 with the FDA, completed our education app, and reinvested in our sales teams. In addition, we completed a reorganization that conservatively extends our cash into 2026. As such, we are reiterating our full year 2023 revenue guidance of at least $64 million, and are able to once again provide an improved Adjusted EBITDA guide for the full year loss of $75 million-$70 million. This is an improvement of an additional $5 million versus our previous number. As a reminder, this guidance reflects revenue that is based on our existing run rate, resources, and product offerings, assuming no large one-time deals occur for the remainder of the year. While there is a strong market that will continue for the iQ+ following the launch of iQ3, we are also factoring in a temporary Osborne effect, where purchases may be delayed pending the launch of the new product. To summarize, the reorganization and the investments we announced in August have been completed, including increasing the direct sales force, launching Butterfly Garden and ScanLab, as well as our submission of iQ3 to the FDA. While our overall revenue is currently facing some headwinds, there is upside to this plan. Furthermore, we have maintained a solid cash position and have once again guided to an improved, Adjusted EBITDA loss. Conservatively, we have a cash runway that takes us into 2026. While this has been a transition year, we are executing against our plan, and the outcome is that we have a company right-sized to accomplish its goals, with a strong base of technological and organizational assets that we are continuing to invest in, and the people who are energized and excited about the future of Butterfly. And with that, I will turn the call back over to Joe for closing remarks. Joe? Thanks, Heather. As you mentioned, 2023 is a transition year. We're resetting, reinvesting, and recharging, preparing for sustained execution and success. We have new leadership, a clear and focused plan, and technology that will take the market. 2024 will be a very good year. We expect to return to double-digit growth, continue to improve our efficiency and cash management, and we'll keep building our AI ecosystem, with Butterfly Garden becoming the AI marketplace for the industry, helping customers gain access to the best ultrasound AI players out there. The candy store shelves are full. We look forward to an Analyst Day in early 2024, where we will unveil even more solutions to come that will have us creating new markets only Butterfly can play in, expanding the market opportunity for Butterfly even further. Thank you for your time, and now I'd like to open it up for questions. We will now begin the question and answer session. If you would like to ask a question, please press star followed by one on your telephone keypad. If for any reason you would like to remove that question, please press star followed by two. Again, to ask a question, press star one. As a reminder, if you are using a speakerphone, please remember to pick up your handset before asking a question. Our first question comes to the line of Josh Jennings with TD Cowen. Your line is now open. Hi, good afternoon. Thanks for the questions, and congratulations on all the pipeline progress. So appreciate the download on iQ3. Great to see. You know, I wanted to just ask Joe about, and Heather, about the return to double-digit revenue growth in 2024. I know there are a couple moving parts, including the Osborne effect in front of the iQ3 launch, it sounds like at the end of 1Q. But maybe just take us through some of the drivers of that return to growth, and then maybe just remind us of some of the comp setups for next year. And as we're forecasting quarterly and for 2024, should we be thinking about a return to double-digit growth in midyear, second half? Maybe if you could take us through the drivers for the U.S. and the international business, and give an update on the kind of restructuring and the commercial infrastructure build-out, rebuild-out internationally. Sorry, there's like three questions in one there, but I'll stop there and just take it. Sorry about that. No problem, Josh. We're happy to answer all of them. The catalyst for us, first of all, you know, we've been spending time, you know, since the last restructuring, strengthening our sales and marketing team, both in the U.S. and international. We've been refining our messaging and our direct-to-consumer marketing. We've been working diligently on our new product launches and understanding, you know, where our customers are today and what it is that we need to grow. We have the largest install base in the world, and we need, you know, to help them. You know, we have a lot of people using probes every day. We have people who have moderate utilization, and we have people who have low utilization. We know that, you know, it's one thing to sell new probes, but as you start building scale, you know, the more same-store sales or the more software that people consume on your base, it also creates unnatural growth. You know, we lost some momentum with all the changes that were made in reorg over the last year, you know, because with a CEO change and then with all the cost cutting that was done earlier in 2023, I feel we lost some momentum, and now we're building it up. The teams are fired up. We have a very clear plan. We know where to sell, we know what levers to pull, and we believe, you know, iQ3 is not the next iPhone, which is great incremental improvements. iQ3 is a step function. It is a significant leap in the evolution of our technology. And by getting and reinforcing the comments that were made, you know, we've done great in individual physician practices and emergency rooms, you know, where all the places where, you know, the jack of all trades really values all the things that Butterfly does. But being able to now penetrate into the subspecialties, to get into cardiac, to get into OB, to get into all the different areas that depend on higher level ultrasound and also cart-based ultrasound, that's the next phase for us. As we go upstream, the training requirements for those customers are less and less and less. So we're gonna be able to start selling upstream more. We're gonna be able to start selling broad-based more on the enterprise side because our software is already doing great, and our enterprise software and our enterprise customers are doing fantastic. We're gonna be focusing now on, you know, a system sell, an enterprise sell that includes our mobile solutions, our hardware, as well as our enterprise software. And we're very bullish on it. And, you know, so yes, we are gonna return to that growth. Also on the international side, we have been working with our partners, we've been working with inventory, we've been resetting our expectations on utilization and our expectations on education, our expectation of our distributors of true organic market development, and they're responding. Our leadership in international right now is second to none. So, I've done this many times. Our team that we have in place are experienced. The company's been through a lot, and now we've had some stability recently, and I think we're starting to get excited about what's to come. So I think you also talked about some... Do you want to talk about some, the other questions he had, or should we ask him to- Yeah, Josh, I- No, that, no- I think we hit on the revenue questions. We hit on the revenue questions. What, you want to ask us to talk about operations at all? Yeah, great. I just within that question, sorry, and it was multilayered. Wanted to just talk about, I guess, the timing of that return to growth. I just don't want to get too aggressive in our forecasting in the early part of the year- Right. - with iQ3- I think- launching Q1, and then just when does international get back to growth? I know you've had some tough comps this year with some strong distributor orders in 2022. And when does that tail off, and could international return to growth earlier than the U.S., or should we be thinking about midyear when that revenue growth really starts to kick in? Thanks for taking the questions. Yeah. Sure. Hi, Josh. I'll take that one. Yeah, I would expect international to come into play sooner than domestic, but we're still working through our 2024 plan and the cadence of that. Obviously, some of it will be dependent on ultimately when we can get the iQ3 launched. So stay tuned, we can give you some additional detail, but we are confident on that double-digit growth over the course of next year. Great. Great. Thanks so much. Thank you for your question. The next question comes from the line of Suraj Kalia with Oppenheimer. Your line is now open. Good afternoon, Joe. Heather, can you hear me all right? Yes. Yes, Suraj, how are you? Hi, Suraj. Doing well. Hope all is well on your end. So Joe, first and foremost, congrats on the quarter in terms- Thank you. ... of stabilizing the business. Forgive me, Joe. Many calls going on at the same time, so if I ask a redundant question, again, apologies. Joe, in terms of direct territories, I know that was one of the things that you had highlighted on the last call, to increase direct territories by, I believe, 40% or 50%, somewhere to that ballpark. Any update on that in terms of where we are? You know, how does the sales rep churn look like? Yeah, it's been the sales rep churn has been very low. We've put the people in place that we've wanted to put in place, and now I think, you know, it's gonna take, you know, six months for them to get up to speed. But as I mentioned in the midpoint of the year, you know, we did allocate the budgets for it, and the team has successfully brought those people on. And so that's one of the things I'm excited about as we get into the early part of 2024. We have, you know, some new additions to the team to augment, you know, a lot of the great people that are here at Butterfly. So those investments have been made, and the people are there. Got it. I have two other follow-up questions, and I'll just pose them together. Heather, one for you, in case you all have quantified or at least directionally given us an idea about a, you know, pending backlog, so to speak, post iQ3 clearance. And Joe, you mentioned something about cart-based systems and going upstream, and I'm not sure I completely understood that. If you could just kind of unspool the thread a little more and talk us about that strategy. Pretty interesting. It seems like a complete shift from where we were. Just as some additional commentary would be greatly appreciated. Thank you for taking my questions. Okay, yeah. So I'll take the first one, Suraj. We don't have a backlog. We're actually not permitted to sell the product until it's been FDA approved, so it's pending approval. So stay tuned. We'll be able to provide some additional information on our next call once we receive approval. And regarding the comment on carts, it's just a function of the type of progress we're able to make with our chip and our processors. You know, between now and say, the next 10, you know, say over the next 10 years, every two years, we're gonna continue to double our processing power and increase our capabilities to get image quality packed into a very small device. And so we're gonna be focusing on all the calculations and settings that exist on carts and create ways for them to present themselves into the devices. We're gonna continue to dramatically increase the power of the device, so the image quality continues to progress at this clip. and we're also gonna work on our workflows in each of the hospitals as to how to manage individual devices, how to store them, charge them, and how to keep them into the workflow. Because the best clinical care is not running to grab a cart or going to a room when a patient needs care. The best clinical care is delivering it to them where they're at, at that moment. And then that means that each doctor will have a Butterfly with them. And as time goes on, there's 60% of medical schools today are teaching ultrasound as a part of their curriculum. 42% of residency programs has it in its curriculum. So over the next decade, people, the doctors are going to be trained on ultrasound, and then they're gonna expect to have it not as, "Oh, let's go do that one scan," but, "Hey, I'm really curious about what's going on here." Instead of you waiting a day and now ordering a scan and having to go someplace or may have to run and get a cart, I'm gonna take care of you right now. And so, you know, we started with this universal device that can do everything, and it's been in all of these different points of care and, you know, right now, we're with all the crises that are happening around the world, the first device charitable organizations are reaching for is Butterfly. And as a part of our growth evolution, is those devices become more and more powerful. You have in your hand today, basically, what would have been the most powerful supercomputer in the world 20 years ago. So think about, you know, open your mind to that. And on, on that supercomputer that you have, that you carry around as your phone, it's also your camera. Why? Because the processing power has been able to now create imaging in, in such a small form factor. So why should a cart exist? If you have an iPhone that is the, the most powerful supercomputer that would have existed, you know, 10, 15, 20 years ago, why would you need a cart in the future if over the next 10 years, we're gonna have five you know, we're gonna have five different doubling terms in processing power? So all the... Imagine all the capabilities that exist in carts are gonna be in a device the size of a Butterfly. Thank you. Thank you for your question. Another question comes from Riley. Your line is now open. Hey, guys. Good afternoon. Thanks for taking our questions. First off, just, How are you guys? Just maybe first off, just on the educational side, just curious, you know, if you can maybe just elaborate a little bit on, you know, any barriers or concerns you've seen on that side with educating users and, you know, how the additional offerings, let's say, ScanLab, may help pull through more probe sales? Well, yeah, I mean, historically, you know, the barrier to education is time and money. You know, we have the time to walk away from our practice and learn something new, and if it's, you know, the best training is when you can actually use your hands and do something. It's hard to just watch videos. And so having that didactic training and then being able to take scans with yourself and then comparing it and learning as you're using is the best way to train. And so our first foray has been Butterfly Academy, which is a series of tests and a series of videos that walk you through how to do it, and it's very, very popular. We have very high utilization, and it's been a great success that our clinical team and education team launched. In order to get people's competency even further, we've now entered into a live training where we can remotely help someone with their didactics, we can remotely help them with their scans with live training, but also we can have instructors come to their site and either educate them individually or educate groups. The only thing that our barrier is in that scenario is time and money. ScanLab is a whole different generation because it's an education-only application, which is designed to help people build their comfort while they're scanning.... Where do you put the probe? What am I looking at? And then being able to see sample videos from that orientation, what it should look at, and then when they get that orientation, to be able to have AI labels that tell them what's the anatomy they're looking at. So it takes it one level further where they can practice as if they're being instructed by an expert, and they can modify their images, they can see what they're doing and be told dynamically in a virtual environment. The time and money aspect, AI really compresses dramatically. Of course, in-person, side-by-side education is the best, and that is the most expensive and the most time-consuming, and that's why, you know, Butterfly Certified exists because we think it's absolutely essential. But Scan Lab will allow med students to start scanning and immediately getting comfortable, almost like a video game, being able to start scanning and then understanding what they're looking at, and we believe will give a lot of comfort in the early development and the early getting over the fear of that initial imaging, will you know create a significant level of comfort. So between Butterfly Academy, looking at videos and understanding and then taking tests between certified and doing it in person, and then Scan Lab, you know, we've, you know, we've come out with, you know, all barrels blazing, trying to get and attack, you know, this part of education. Now, also, you know, new advanced AI tools like our bladder scanner or like our new B-Line tool, also makes and that's why AI is so important. AI is so important because there's ways to capture images in a more automated fashion or guide people how to capture images in a more automated fashion. There's ways to read images in a more automated fashion, and so getting more and more people and healthcare professionals who don't have prior experience to use these AI tools is really essential. And so that's why Butterfly Garden is so powerful, because we now allow all of these excellent AI tools that other companies have developed to exist in the Butterfly environment, so our customers and our Butterfly users now will have access to those tools. So, you know, in every phase of development of ultrasound, whether it's early education with AI, whether it's video and testing, whether it's in-person education, or now using advanced AI tools, Butterfly will be the environment that everyone goes to. Great. Thanks for that, that additional color. Just, maybe just on the Forest Neurotech agreement, just curious if you could, you know, elaborate more on just kind of next steps there and kind of the brain computer interface market, and just kind of how to think about milestones towards commercialization? Well, you know, I think I don't wanna speak for Forest. That is really their business and their opportunity. What I will say is Butterfly investors have invested over $500 million in developing an incredibly novel semiconductor technology that has wide application. It has tremendous application within point-of-care ultrasound and ultrasound imaging, but it has incredible application in other markets. And we've identified the markets that Butterfly will go after, and we will partner with other companies, so they don't have to make the $500 million investment, but also our investors get to benefit from those developments. What's exciting about the Forest particular deal is what they're looking for is the automatic scanning capability that only a semiconductor can do. You'd have to move, you'd have to have a windshield wiper-type device at the top of the brain to move a probe back and forth, in order to get the type of scan that we provide. You know, our scanning, we can put the chip at the top, and then we'd be able to scan through the entire brain, just like in Star Trek, you know, the tricorder that Bones had, you just put it in front of someone, and it would scan your body. That's what our semiconductor can do, and it makes it really easy for them to deliver their technology to do deep brain stimulation and other types of therapies using ultrasound. So, you know, we're gonna let them develop their clinical applications, but allow for an innovation that they're developing to come to market so much quicker because it stands upon, upon a proven platform. They would have had to go through, you know, the seven years, 10, 11 years of evolution, development and, you know, $500 million worth of investment to be able to get to where... You know, they don't have to worry about that processor. They can just focus on their therapy. And the beautiful part for, for, for Butterfly investors is not only are we getting paid for the work, and not only are we getting rewarded and recouping some of our investment, but on their commercial success, we'll be a part of their commercial success with them and have revenue on every unit they sell. If we can continue to develop our Butterfly ecosystem and have revenue pass through for new AI applications, and if we can continue to monetize our semiconductor technology in non-competitive markets, it increases the value of Butterfly and helps us get to our goals faster. Great. That's it for me. Thanks. Awesome. Thanks, Neil. Thanks, Neil. Thank you for your question. There are no additional questions waiting at this time. I would now like to pass the conference back to Joe for further remarks. Well, thank you all for joining. We're very excited about where we are. We know we're in a transition. We're mindful as to exactly where the company is, and I'd have to say, you know, we're excited about 2024 and the developments. So stay tuned. We'll unpack iQ3 and the software and the power of iQ3 at our next quarter's conference call. So thank you. That concludes today's call. Thank you for your participation, and enjoy the rest of your day.